Femasys Inc. (NASDAQ:FEMY) Short Interest Up 106.2% in February

Femasys Inc. (NASDAQ:FEMY) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 298,300 shares, an increase of 106.2% from the January 31st total of 144,700 shares. Approximately 1.4% of the company’s stock are sold short. Based on an average daily volume of 275,300 shares, the short-interest ratio is currently 1.1 days.

Femasys Stock Down 1.3 %

FEMY stock traded down $0.02 during midday trading on Friday, hitting $1.57. The company’s stock had a trading volume of 145,280 shares, compared to its average volume of 275,784. The firm’s 50-day moving average is $1.24 and its 200-day moving average is $1.17. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys has a 12 month low of $0.86 and a 12 month high of $2.40. The company has a market cap of $35.95 million, a PE ratio of -1.94 and a beta of -2.81.

Institutional Investors Weigh In On Femasys

Large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of Femasys during the 4th quarter valued at about $25,000. Aljian Capital Management LLC bought a new stake in Femasys during the 3rd quarter worth approximately $27,000. Jane Street Group LLC bought a new stake in Femasys during the 4th quarter worth approximately $30,000. XTX Topco Ltd lifted its holdings in Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Femasys in the fourth quarter worth $45,000. 65.27% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Femasys in a report on Wednesday. Chardan Capital dropped their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.